Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 12;2(1):32.
doi: 10.1186/2045-3701-2-32.

Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy

Affiliations

Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy

Hailiu Yang et al. Cell Biosci. .

Abstract

Human Immunodeficiency Virus Type 1 (HIV-1) protease inhibitors (PIs) are the most potent class of drugs in antiretroviral therapies. However, viral drug resistance to PIs could emerge rapidly thus reducing the effectiveness of those drugs. Of note, all current FDA-approved PIs are competitive inhibitors, i.e., inhibitors that compete with substrates for the active enzymatic site. This common inhibitory approach increases the likelihood of developing drug resistant HIV-1 strains that are resistant to many or all current PIs. Hence, new PIs that move away from the current target of the active enzymatic site are needed. Specifically, allosteric inhibitors, inhibitors that prohibit PR enzymatic activities through non-competitive binding to PR, should be sought. Another common feature of current PIs is they were all developed based on the structure-based design. Drugs derived from a structure-based strategy may generate target specific and potent inhibitors. However, this type of drug design can only target one site at a time and drugs discovered by this method are often associated with strong side effects such as cellular toxicity, limiting its number of target choices, efficacy, and applicability. In contrast, a cell-based system may provide a useful alternative strategy that can overcome many of the inherited shortcomings associated with structure-based drug designs. For example, allosteric PIs can be sought using a cell-based system without considering the site or mechanism of inhibition. In addition, a cell-based system can eliminate those PIs that have strong cytotoxic effect. Most importantly, a simple, economical, and easy-to-maintained eukaryotic cellular system such as yeast will allow us to search for potential PIs in a large-scaled high throughput screening (HTS) system, thus increasing the chances of success. Based on our many years of experience in using fission yeast as a model system to study HIV-1 Vpr, we propose the use of fission yeast as a possible surrogate system to study the effects of HIV-1 protease on cellular functions and to explore its utility as a HTS system to search for new PIs to battle HIV-1 resistant strains.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Life cycle of the HIV-1. Life cycle of HIV-1 occurs in 6 major steps: 1) adsorption and fusion of viral particle, 2) reverse transcription by Reverse Transcriptase, 3) integration of viral dsDNA into genomic DNA by Integrase, 4) expression of viral genes, 5) cleavage of Gag-pol and Gag precursor by HIV-1 PR and assembly of proteins into mature viral particle, and 6) budding of mature virion from host cell.
Figure 2
Figure 2
Structure of HIV-1 protease bound to TL-3, a competitive protease inhibitor. Figure was obtained with permission from [9].

Similar articles

Cited by

References

    1. WHO. Progress Report 2011. World Health Organization (WHO), Geneva, Switzerland; 2011. Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access; pp. 1–224.
    1. Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol. 2004;78:3123–3132. doi: 10.1128/JVI.78.6.3123-3132.2004. - DOI - PMC - PubMed
    1. Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Aids. 1999;13:661–667. - PMC - PubMed
    1. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010;54:4253–4261. doi: 10.1128/AAC.00574-10. - DOI - PMC - PubMed
    1. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des. 2004;10:4039–4053. doi: 10.2174/1381612043382440. - DOI - PubMed